Gene
EREG
EREG is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (10), Actionable biomarkers (1), Trial mentions (1), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention EREG. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 dated before 1990 and 83 at the structurally incomplete recent edge.
EREG has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 156 of 11,460 | 1.36% |
| 2022 | 0 of 8,285 | 0.00% | 204 of 13,598 | 1.50% |
| 2021 | 0 of 8,692 | 0.00% | 193 of 15,045 | 1.28% |
| 2020 | 0 of 7,640 | 0.00% | 200 of 14,459 | 1.38% |
| 2019 | 0 of 7,300 | 0.00% | 167 of 12,159 | 1.37% |
| 2018 | 0 of 6,927 | 0.00% | 133 of 11,854 | 1.12% |
| 2017 | 0 of 6,558 | 0.00% | 157 of 11,595 | 1.35% |
Showing 10 of 37 years.
Assay-provider ledger (10)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| RayBiotech, Norcross, GA, USA | Reagent supplier | Clinical validationAnalytical validation | 1 | April 01, 2019 |
| Mitra Biotech | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | May 04, 2017 |
| Abd Serotec, UK | Reagent supplier | Clinical validation | 1 | January 31, 2017 |
| Bioss, USA | Reagent supplier | Clinical validation | 1 | January 31, 2017 |
| Dako UK Ltd | Context dependent | Clinical validation | 1 | January 31, 2017 |
Showing 5 of 10 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| EREG amplification | Egfr Mab Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07094893 | Trial eligibility (AACT) |
Target-disease associations (332)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Angiomyxoma | cancer or benign tumor | Literature (Europe PMC) |
| Autosomal recessive early-onset inflammatory bowel disease | gastrointestinal disease | Mouse knockout (IMPC) |
| Bartsocas-Papas syndrome 1 | genetic, familial or congenital disease | Literature (Europe PMC) |
| C-X-C motif chemokine 10 measurement | measurement | GWAS credible sets |
Showing 5 of 332 associations.
Vendor sourcing (6)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.176G>A (p.R59H) alteration is located in exon 3 (coding exon 3) of the EREG gene. This alteration results from a G to A substitution at nucleotide posi... | View ClinVar record SCV003592606.3 |
| Gruppo Oncologico del Nord Ovest | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for Registration: * Age ≥18 years * Biopsy-confirmed adenocarcinoma of the colon with a right primary tumour location * aCRC defined as either M1 or locally... | View trial NCT07094893 |
| Gruppo Oncologico del Nord Ovest | Trial sponsor | Mentioned in trial textTrial free-text mention | EREG | View trial NCT07094893 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001120446.1 |
| Merck Serono International SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | for Registration: * Age ≥18 years * Biopsy-confirmed adenocarcinoma of the colon with a right primary tumour location * aCRC defined as either M1 or locally... | View trial NCT07094893 |
Showing 5 of 6 sourcing records.
Trial-cited literature (2,207)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The effect of three daily servings of full-fat dairy for 12 weeks on body weight, body composition, energy metabolism, blood lipids, and dietary intake of adults with overweight and obesity. | The Journal of nutrition | 2026 | 2 |
| OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy. | Future oncology (London, England) | 2026 | 1 |
| Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trial. | Nature medicine | 2025 | 119 |
| Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. | Nature medicine | 2025 | 99 |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
Showing 5 of 2,207 papers.
Protein variant mentions (11)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A67I | 1 | 2010 | PMID 19910132 |
| p.C50I | 1 | 2010 | PMID 19910132 |
| p.D80I | 1 | 2010 | PMID 19910132 |
| p.E84I | 1 | 2010 | PMID 19910132 |
| p.F70I | 1 | 2010 | PMID 19910132 |
Showing 5 of 11 variants.
Literature-extracted relations (407)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Letrozole | Chemical | positive_correlate |
Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study. | 2025 |
| Platinum | Chemical | positive_correlate |
Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study. | 2025 |
| Hydrogen | Chemical | positive_correlate |
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. | 2025 |
| CARBOPLATIN | Chemical | negative_correlate |
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. | 2025 |
| DOCETAXEL | Chemical | negative_correlate |
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. | 2025 |
Showing 5 of 407 relation assertions.
Organizations publishing (1,105)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 91 | 2010 to 2025 |
| Dana-Farber Cancer Institute | Other | 83 | 2008 to 2025 |
| Harvard Medical School | Academic | 79 | 2010 to 2025 |
| Mayo Clinic | Hospital | 62 | 2007 to 2025 |
| The University of Texas System | Academic | 59 | 2009 to 2025 |
Showing 5 of 1,105 organizations.
Where EREG appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
324 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.